Perroud et al. postulated that the high expression in BC of the prostaglandin synthase enzyme cyclooxygenase-2 (COX2) could be a reasonable basis to combine metronomic CTX with the anti-COX2 agent celecoxib. This evidence concerns the gene PTGS2 and breast cancer.